A Phase 2 interventional study of Radiation and Irinotecan in Metastatic Colorectal Cancer, sponsored by Institut Cancerologie de l'Ouest. Completed at 6 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.
Sponsored by Institut Cancerologie de l'Ouest · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 200 studies testing irinotecan in Colorectal Neoplasms — 25 open to participants now, 32 under way, 6 of them phase 3. Irinotecan · Colorectal Neoplasms.
Among the 200 studies testing irinotecan in Colorectal Neoplasms, this one is the 89th largest by enrollment of the 182 interventional ones that give a count, is one of 12 that started in 2007, is one of 117 in phase 2, and was the 112th registered.
6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →25 of the 200 studies testing irinotecan in Colorectal Neoplasms are open now, in 8 countries. Recruiting first, the newest first:
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Sites in China
Ages 18+
Gruppo Oncologico Italia Meridionale · Sites in Italy
Ages 18+
Sun Yat-sen University · Sites in China
Ages 18–80
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Sites in China
Ages 18–70
Shanghai Zhongshan Hospital · Sites in China
Ages 18–75
By country, each count listing its studies:
Irinotecan: first FDA approval 1996 (CAMPTOSAR), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
200 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 48 · Phase 2 139 · Phase 3 28 · Phase 4 2
First in 1996; this study’s year is marked. 12 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 47 is below the median of 76 across 4,811 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 47 across the 182 interventional studies. Of the 131 that completed or were terminated, 27 (21%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 200 have an industry lead sponsor. The 10 most frequent:
Institut Cancerologie de l'Ouest is the lead sponsor of 109 studies on the registry; 20 are open to participants now.
Institut Cancerologie de l'Ouest has 6 studies filed under Colorectal Neoplasms — fewer than ten, so there is no comparison to draw.
7 of the studies testing irinotecan in Colorectal Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03303495Phase 3Sun Yat-sen UniversityA Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC | 2026-12-31 |
| NCT06321081Beijing HospitalICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC | 2026-12-30 |
| NCT07229846Yanqiao ZhangA Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E Mutation | 2027-02 |
| NCT05391126Reema A. PatelGENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care | 2027-05 |
| NCT07570914Tianjin Medical University Cancer Institute and HospitalHepatic Arterial Infusion of Liposomal Irinotecan Plus Oxaliplatin and Capecitabine as Adjuvant Therapy for Colorectal Cancer Liver Metastases | 2027-05-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 200 studies testing irinotecan in Colorectal Neoplasms, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to study stereotactic radiotherapy with a dose of 40 Gy in 4 fractions over 2 weeks with concomitant 40 mg/m2 of irinotecan (1st and 3rd irradiation session).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients must have received at least one prior chemotherapy regimen containing 5FU
Exclusion Criteria:
Pregnancy or breastfeeding.
- Lack of means or refusal to use effective for men or women of childbearing age.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Irinotecan will be administered : \- 40 mg/m² in serum physiologique during 30 to 90 min at D1 and D8 of radiotherapy Radiotherapy (RSHF) will be administered : * at D1, D3, D8 and D10 * 48 Gy, 12 Gy by fractions twice a week
Radiation: Radiation · Drug: Irinotecan
10 Gy for 4 times (total 40 Gy)
Also known as: RSHF
40 mg/m² : Day 1 and day 8
Also known as: Campto
Objective Tumor Response Rate of Irradiated Lesions
The primary objective is to increase the tumor response rate following stereotactic radiotherapy delivered at a total dose of 48 Gy in 4 fractions over 2 weeks, administered concomitantly with irinotecan at 40 mg/m² (on the 1st and 3rd irradiation sessions). Tumor response of the irradiated site will be assessed according to RECIST criteria by an investigator review committee, based on thoracic or hepatic CT imaging. Objective response is defined as the percentage of patients achieving either a complete response (CR) or a partial response (PR).
Time frame: 48 months
Progression-Free Survival at 1 Year
Progression-free survival (PFS) is defined as the time from the start of treatment to the first occurrence of disease progression (local or distant) or death from any cause. Progression will be assessed according to RECIST criteria based CT imaging. The 1-year PFS rate corresponds to the percentage of patients alive without disease progression at 12 months after treatment initiation.
Time frame: 1 year
| Milestone | Radiation + Irinotecan |
|---|---|
| Started | 47 |
| Completed | 47 |
| Not completed | 0 |
The primary objective is to increase the tumor response rate following stereotactic radiotherapy delivered at a total dose of 48 Gy in 4 fractions over 2 weeks, administered concomitantly with irinotecan at 40 mg/m² (on the 1st and 3rd irradiation sessions). Tumor response of the irradiated site will be assessed according to RECIST criteria by an investigator review committee, based on thoracic or hepatic CT imaging. Objective response is defined as the percentage of patients achieving either a complete response (CR) or a partial response (PR).
| Participants | Radiation + Irinotecan |
|---|---|
| Objective Tumor Response Rate of Irradiated Lesions | 42 |
Progression-free survival (PFS) is defined as the time from the start of treatment to the first occurrence of disease progression (local or distant) or death from any cause. Progression will be assessed according to RECIST criteria based CT imaging. The 1-year PFS rate corresponds to the percentage of patients alive without disease progression at 12 months after treatment initiation.
| Participants | Radiation + Irinotecan |
|---|---|
| Progression-Free Survival at 1 Year | 18 |
Collected over 1 year. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Radiation + Irinotecan | 2/47 (4.3%) | 7/47 (14.9%) | 39/47 (83%) |
| Event | Radiation + Irinotecan |
|---|---|
| Budd-Chiari syndromeBlood and lymphatic system disorders | 1/47 |
| Abdominal painGastrointestinal disorders | 1/47 |
| DiarrhoeaGastrointestinal disorders | 1/47 |
| JaundiceHepatobiliary disorders | 1/47 |
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 1/47 |
| Septic shockInfections and infestations | 1/47 |
| sepsisInfections and infestations | 1/47 |
| Event | Radiation + Irinotecan |
|---|---|
| DiarrhoeaGastrointestinal disorders | 17/47 |
| astheniaGeneral disorders | 13/47 |
| vomitingGastrointestinal disorders | 8/47 |
| anorexiaGeneral disorders | 3/47 |
| anxietyPsychiatric disorders | 3/47 |
| Age, Categorical(Participants) | Radiation + Irinotecan |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 21 |
| >=65 years | 26 |
| Sex: Female, Male(Participants) | Radiation + Irinotecan |
|---|---|
| Female | 0 |
| Male | 47 |
| Race and Ethnicity Not Collected(Participants) | Radiation + Irinotecan |
|---|
| Region of Enrollment(participants) | Radiation + Irinotecan |
|---|---|
| France | 47 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2007 to primary completion in Aug 2018, 130 months.
Results were first posted in Oct 2026, 8 years 2 months after primary completion.
Of 499 non-industry phase 2 interventional studies under Colorectal Neoplasms, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 75. This study's 130 months is above that.
Counting every sponsor, half of 619 studies reached it within 49 months; a quarter within 31 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Irinotecan
Institut Cancerologie de l'Ouest →